Bone marrow aspiration enhances detection of leukemia cells

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 18 No 11
Volume 18
Issue 11

Scientists in New Mexico are experimenting with a nanotechnology device that quantifies the amount of nanoparticle-bound tumor cells in a tissue sample and offers increased sensitivity to minimal residual disease (Cancer Res 69:6839-6847, 2009).

Scientists in New Mexico are experimenting with a nanotechnology device that quantifies the amount of nanoparticle-bound tumor cells in a tissue sample and offers increased sensitivity to minimal residual disease (Cancer Res 69:6839-6847, 2009).

The marrow biopsy needle targets tumor cells with nanoparticles and then preferentially extracts the cells with a magnetic needle. The group used anti-CD34 antibody loaded magnetic nanoparticles to detect CD34-positive cells as an indicator of leukemia. To quantify the cells recovered, they coupled this nanoparticle-mediated fishing for leukemic cells with the Superconducting Quantum Interference Device (SQUID).

The work is a collaborative effort between Senior Scientific and the University of New Mexico Health Science Center, both in Albuquerque.

Recent Videos
Data from the SPOTLIGHT and GLOW trials reveal that zolbetuximab increased survival in patients with CLDN18.2-positive gastric or GEJ adenocarcinoma.
The incorporation of zolbetuximab in addition to chemotherapy has shown benefit in patients with Claudin 18.2–positive gastric cancers in clinical trials.
Michael J. Hall, MD, MS, FASCO, discusses the need to reduce barriers to care for those with Li-Fraumeni syndrome, including those who live in rural areas.
Patrick Oh, MD, highlights next steps for further research in treating patients with systemic therapy in addition to radiotherapy for early-stage NSCLC.
The ability of metformin to disrupt mitochondrial metabolism may help mitigate the risk of cancer in patients with Li-Fraumeni syndrome.
Related Content